• Glaukos recently completed patient enrollment in its U.S. 510(k) pivotal study of the PRESERFLO MicroShunt for adults with primary open-angle glaucoma who have not responded to prior medical and surgical treatments, reaching at least 110 participants across U.S. and Canadian sites.
• This milestone moves the PRESERFLO MicroShunt closer to potential FDA submission, adding another minimally invasive glaucoma option alongside growing real-world use in markets such as Canada and Australia.
• Next, we’ll examine how this pivotal trial milestone for the PRESERFLO MicroShunt could influence Glaukos’ long-term glaucoma pipeline story.

We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Glaukos Investment Narrative Recap

To own Glaukos, you generally need to believe that interventional glaucoma and corneal therapies can support meaningful, durable demand despite competition and reimbursement pressure. Completion of PRESERFLO’s U.S. pivotal enrollment is a step toward another glaucoma device, but it does not materially change the most immediate catalysts around iDose TR usage and Epioxa uptake, or the key risk that heavy R&D and commercialization spend continues while the company remains unprofitable.

The most directly related recent catalyst is Glaukos’ January 2026 FDA labeling update allowing repeat administration of iDose TR. Together with the PRESERFLO pivotal trial milestone, this highlights a broadening interventional glaucoma toolkit that could matter for long term pipeline diversification, even as shorter term results still hinge on execution with iDose TR and early Epioxa adoption.

Yet despite this progress, investors should be aware that reimbursement pressure on ophthalmic procedures could still...

Glaukos’ narrative projects $1.1 billion revenue and $113.0 million earnings by 2029.

Uncover how Glaukos' forecasts yield a $165.00 fair value, a 7% upside to its current price.

Exploring Other Perspectives

While today’s PRESERFLO milestone may support the long term glaucoma story, the more pessimistic analysts were already assuming revenue of about US$890.7 million and only US$60.7 million in earnings by 2029, so you should expect that their view of reimbursement and competition risk could shift meaningfully as this new data comes through.

Explore 4 other fair value estimates on Glaukos - why the stock might be worth 11% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Glaukos research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Glaukos research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Glaukos' overall financial health at a glance.

Interested In Other Possibilities?

Our top stock finds are flying under the radar-for now. Get in early:

• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.